Glaukos Corporation (GKOS)

Market Cap	2.29B
Revenue (ttm)	284.88M
Net Income (ttm)	-89.61M
Shares Out	47.70M
EPS (ttm)	-1.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	325,546
Open	48.06
Previous Close	48.18
Day's Range	47.15 - 48.29
52-Week Range	33.33 - 64.49
Beta	1.20
Analysts	Buy
Price Target	58.55 (+21.88%)
Earnings Date	Feb 20, 2023

About GKOS

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; a...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Thomas Burns
• Employees: 727
• Stock Exchange: NYSE
• Ticker Symbol: GKOS

Financial Performance

In 2021, Glaukos's revenue was $294.01 million, an increase of 30.70% compared to the previous year's $224.96 million. Losses were -$49.59 million, -58.79% less than in 2020.

Analyst Forecast

According to 18 analysts, the average rating for GKOS stock is "Buy." The 12-month stock price forecast is $58.55, which is an increase of 21.88% from the latest price.

Price Target

$58.55

(21.88% upside)

Analyst Consensus: Buy